Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Value Health Reg Issues ; 42: 100983, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38663057

ABSTRACT

OBJECTIVES: To evaluate cost-effective pharmacological treatment in adult kidney transplant recipients from the perspective of the Colombian health system. METHODS: A decision tree model for the induction phase and a Markov model for the maintenance phase were built. A review of the clinical literature was conducted to extract probabilities, and the life-years were used as the outcome. Costs were calculated using the administrative databases. The evaluating treatment schemes are organized by groups of evidence with direct comparisons. RESULTS: In the induction phase, anti-thymocyte immunoglobulin+ methylprednisolone is dominant, more effective, and less expensive, compared with basiliximab+methylprednisolone. In the maintenance phase, azathioprine (AZA) is dominant in contrast to mycophenolate mofetil (MFM) both with cyclosporine (CIC)+ corticosteroids (CE); CIC is dominant relative to sirolimus (SIR) and tacrolimus (TAC) (both with MFM+CE or AZA+CE), and TAC is dominant compared with SIR (in addition with MFM+CE or mycophenolate sodium [MFS]+CE); MFM is dominant in relation to MFS and everolimus, and SIR is more effective MFM but it does not exceed the threshold (in sum with TAC+CE); MFS and MFM are dominant relative to everolimus, and SIR is more effective than MFM, but it does not exceed the threshold (in addiction with CIC+CE); MFM is dominant in relation to TAC (in sum with SIR+CE), and CIC+AZA+CE is dominant in relation to TAC+MFM+CE. CONCLUSIONS: The base-case results for all evidence groups are consistent with the different sensitivity analyses.


Subject(s)
Immunosuppressive Agents , Kidney Transplantation , Adult , Humans , Adrenal Cortex Hormones/therapeutic use , Adrenal Cortex Hormones/economics , Azathioprine/therapeutic use , Azathioprine/economics , Colombia , Cost-Effectiveness Analysis , Cyclosporine/therapeutic use , Cyclosporine/economics , Decision Trees , Graft Rejection/prevention & control , Graft Rejection/economics , Immunosuppressive Agents/economics , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/economics , Markov Chains , Mycophenolic Acid/therapeutic use , Mycophenolic Acid/economics , Sirolimus/therapeutic use , Sirolimus/economics , Tacrolimus/economics , Tacrolimus/therapeutic use , Transplant Recipients/statistics & numerical data
2.
Ann Vasc Surg ; 40: 327-334, 2017 Apr.
Article in English | MEDLINE | ID: mdl-27903479

ABSTRACT

BACKGROUND: The use of a prophylactic antibiotic in an amputation surgery is a key element for the successful recovery of the patient. We aim to determine, from the perspective of the Colombian health system, the cost-effectiveness of administering a prophylactic antibiotic among patients undergoing lower limb amputation due to diabetes or vascular illness in Colombia. METHODS: A decision tree was constructed to compare the use and nonuse of a prophylactic antibiotic. The probabilities of transition were obtained from studies identified from a systematic review of the clinical literature. The chosen health outcome was reduction in mortality due to prevention of infection. The costs were measured by expert consensus using the standard case methodology, and the resource valuation was carried out using national-level pricing manuals. Deterministic sensitivity, scenarios, and probabilistic analyses were conducted. RESULTS: In the base case, the use of a prophylactic antibiotic compared with nonuse was a dominant strategy. This result was consistent when considering different types of medications and when modifying most of the variables in the model. The use of a prophylactic antibiotic ceases to be dominant when the probability of infection is greater than 48%. CONCLUSIONS: The administration of a prophylactic antibiotic was a dominant strategy, which is a conclusion that holds in most cases examined; therefore, it is unlikely that the uncertainty around the estimation of costs and benefits change the results. We recommend creating policies oriented toward promoting the use of a prophylactic antibiotic during amputation surgery in Colombia.


Subject(s)
Amputation, Surgical/economics , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/economics , Antibiotic Prophylaxis/economics , Diabetic Angiopathies/economics , Diabetic Angiopathies/surgery , Drug Costs , Lower Extremity/blood supply , Peripheral Vascular Diseases/economics , Peripheral Vascular Diseases/surgery , Surgical Wound Infection/economics , Surgical Wound Infection/prevention & control , Amputation, Surgical/adverse effects , Amputation, Surgical/mortality , Colombia , Cost-Benefit Analysis , Decision Support Techniques , Decision Trees , Diabetic Angiopathies/diagnosis , Diabetic Angiopathies/mortality , Drug Administration Schedule , Humans , Models, Economic , Peripheral Vascular Diseases/diagnosis , Peripheral Vascular Diseases/mortality , Surgical Wound Infection/microbiology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL